Skip to search formSkip to main contentSkip to account menu

PAI 039

Known as: PAI-039, PAI039 cpd 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Background: Plasminogen activator inhibitor (PAI)-1 levels and activity are known to increase during metabolic syndrome and… 
2015
2015
BackgroundAn increased incidence of venous thromboembolism (VTE) is associated with anti-vascular endothelial growth factor (VEGF… 
2012
2012
Spatial and temporal regulation of the pericellular proteolytic environment by local growth factors, such as EGF and TGF… 
2008
2008
Summary.  Objective: To assess the antithrombotic and profibrinolytic effects of tiplaxtinin (PAI‐039), an orally bioavailable… 
Highly Cited
2006
Highly Cited
2006
Objective—The effect of a novel small molecule plasminogen activator inhibitor (PAI-1) inhibitor on adipose tissue physiology was… 
Highly Cited
2006
Highly Cited
2006
Summary.  Background: Plasminogen activator inhibitor‐1 (PAI‐1) is integrally involved in tumorigenesis by impacting on both… 
2005
2005
We tested a novel, orally active inhibitor of plasminogen activator inhibitor-1 (PAI-1) in a canine model of electrolytic injury… 
Highly Cited
2005
Highly Cited
2005
Objective— To test the hypothesis that pharmacological plasminogen activator inhibitor (PAI)-1 inhibition protects against renin…